Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $19.90 in the prior trading day, Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) closed at $18.65, down -6.28%. In other words, the price has decreased by -$6.28 from its previous closing price. On the day, 1.26 million shares were traded. KNSA stock price reached its highest trading level at $19.68 during the session, while it also had its lowest trading level at $18.29.
Ratios:
Our goal is to gain a better understanding of KNSA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 53.32. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $40.
On September 13, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $40.
On May 03, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $34.Wells Fargo initiated its Overweight rating on May 03, 2024, with a $34 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 20 ’25 when Ragosa Mark sold 15,944 shares for $23.11 per share. The transaction valued at 368,466 led to the insider holds 23,382 shares of the business.
Ragosa Mark sold 11,464 shares of KNSA for $264,818 on Mar 17 ’25. The CHIEF FINANCIAL OFFICER now owns 23,382 shares after completing the transaction at $23.10 per share. On Mar 19 ’25, another insider, Ragosa Mark, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 8,879 shares for $23.10 each. As a result, the insider received 205,105 and left with 23,382 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KNSA now has a Market Capitalization of 1354814336 and an Enterprise Value of 1245264768. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.20 while its Price-to-Book (P/B) ratio in mrq is 3.08. Its current Enterprise Value per Revenue stands at 2.942 whereas that against EBITDA is -28.352.
Stock Price History:
The Beta on a monthly basis for KNSA is 0.13, which has changed by 0.07865822 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, KNSA has reached a high of $28.15, while it has fallen to a 52-week low of $16.56. The 50-Day Moving Average of the stock is -10.93%, while the 200-Day Moving Average is calculated to be -16.99%.
Shares Statistics:
The stock has traded on average 624.73K shares per day over the past 3-months and 774170 shares per day over the last 10 days, according to various share statistics. A total of 41.88M shares are outstanding, with a floating share count of 40.15M. Insiders hold about 44.73% of the company’s shares, while institutions hold 56.59% stake in the company. Shares short for KNSA as of 1741910400 were 3072555 with a Short Ratio of 5.01, compared to 1739491200 on 2961419. Therefore, it implies a Short% of Shares Outstanding of 3072555 and a Short% of Float of 9.379999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Kiniksa Pharmaceuticals International Plc (KNSA) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.27, with high estimates of $0.45 and low estimates of -$0.09.
Analysts are recommending an EPS of between $1.69 and $0.2 for the fiscal current year, implying an average EPS of $1.03. EPS for the following year is $1.75, with 4.0 analysts recommending between $2.65 and $0.52.
Revenue Estimates
7 analysts predict $132.22M in revenue for the current quarter. It ranges from a high estimate of $147.19M to a low estimate of $123M. As of the current estimate, Kiniksa Pharmaceuticals International Plc’s year-ago sales were $79.86MFor the next quarter, 7 analysts are estimating revenue of $141.93M. There is a high estimate of $149.07M for the next quarter, whereas the lowest estimate is $137.7M.
A total of 7 analysts have provided revenue estimates for KNSA’s current fiscal year. The highest revenue estimate was $610.21M, while the lowest revenue estimate was $569.8M, resulting in an average revenue estimate of $584.1M. In the same quarter a year ago, actual revenue was $423.24MBased on 7 analysts’ estimates, the company’s revenue will be $703.4M in the next fiscal year. The high estimate is $732M and the low estimate is $676.65M.
